Botulinum toxin a (dysport®): In dystonias and focal spasticity

Drugs

Volumn 71, Issue 8, 2011, Pages 1043-1058

  Keam, Susan J ^a   Muir, Victoria J ^a   Deeks, Emma D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Blepharospasm; Botulinum toxin A; Dystonia; general; Muscle spasticity; Torticollis; treatment

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ACCIDENTAL INJURY; AMBLYOPIA; ARTICLE; ASPIRATION PNEUMONIA; ASTHENIA; BLEPHAROSPASM; BLURRED VISION; CEREBRAL PALSY; CERVICAL DYSTONIA; DIARRHEA; DIPLOPIA; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRY EYE; DYSPHAGIA; DYSTONIA; EYELID EDEMA; FATIGUE; FLU LIKE SYNDROME; GAIT DISORDER; HEMIFACIAL SPASM; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE PAIN; LACRIMATION; LAGOPHTHALMOS; MUSCLE WEAKNESS; MYASTHENIA; NONHUMAN; PES EQUINUS; PHARMACODYNAMICS; PTOSIS; RASH; SIDE EFFECT; SPASTICITY; URINE INCONTINENCE; VOMITING; WEAKNESS; XEROSTOMIA;

BOTULINUM TOXINS, TYPE A; CHOLINERGIC ANTAGONISTS; DYSTONIC DISORDERS; HUMANS; MUSCLE SPASTICITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79958834885     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11206340-000000000-00000     Document Type: Article

References (53)

1. National Institute of Neurological Disorders and Stroke. Dystonias fact sheet [online]. Available from URL: http://www.ninds.nih.gov/disorders/ dystonias/detail-dystonias.htm [Accessed 2010 Oct 22].
2. The Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. A prevalence study of primary dystonia in eight European countries. J Neurol 2000Oct; 247 (10): 787-92.
3. Velickovic M, Benabou R, Brin MF. Cervical dystonia pathophysiology and treatment options. Drugs 2001; 61 (13): 1921-43. (Pubitemid 33702490)
4. Defazio G, Livrea P. Primary blepharospasm: diagnosis and management. Drugs 2004; 64 (3): 237-44. (Pubitemid 38283042)
5. WE MOVE - Worldwide Education and Awareness for Movement Disorders. Spasticity - epidemiology [online]. Available from URL: http://www.wemove.org/ spa/spa-epi.html [Accessed 2010 Oct 25].
6. Sheean G. Botulinum toxin treatment of adult spasticity: a benefit-risk assessment. Drug Saf 2006; 29 (1): 31-48. (Pubitemid 43213894)
7. Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009 Jan; 41 (1): 13-25.
8. Heinen F, Desloovere K, Schroeder AS, et al. The updated European Consensus 2009 on the use of botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2010 Jan; 14 (1): 45-66.
9. Koman LA, Paterson Smith B, Balkrishnan R. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Paediatr Drugs 2003; 5 (1): 11-23. (Pubitemid 36127021)
10. Thakker MM, Rubin PA. Pharmacology and clinical applications of botulinum toxins A and B. Int Ophthalmol Clin 2004 Summer; 44 (3): 147-63. (Pubitemid 38955667)
11. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000 Apr; 80 (2): 717-66. (Pubitemid 30164948)
12. Aoki KR. Pharmacology and immunology of botulinum neurotoxins. Int Ophthalmol Clin 2005 Summer; 45 (3): 25-37. (Pubitemid 41022173)
13. Ipsen Pharmaceuticals. Dysport for injection (abobotulinumtoxinA): US prescribing information [online]. Available from URL: http://www.dysport.com/ pdf/prescribinginformation.pdf [Accessed 2011 May 11].
14. Ipsen Pharmaceuticals. Dysport: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/870/SPC/ Dysport/ [Accessed 2010 Sep 13].
15. Figgitt DP, Noble S. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia. Drugs 2002; 62 (4): 705-22. (Pubitemid 34264034)
16. Allergan Ltd. BOTOX: summary of product characteristics [online]. Available from URL: http://www.medicines.org. uk/emc/medicine/112 [Accessed 2010 Oct 26].
17. Merz Pharma. Xeomin: summary of product characteristics [online]. Available from URL: http://www.medicines.org. uk/emc/document.aspx?documentId= 20666 [Accessed 2010 Oct 26].
18. Eisai Ltd. NeuroBloc-5000 U/mL solution for injection: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/ medicine/ 20568/SPC/NeuroBloc++5000+U+ml+solution+for+injec tion/ [Accessed 2011 Mar 10].
19. Solstice Neurosciences. Myobloc-(rimabotulinumtoxinB): US prescribing information [online]. Available from URL: http://www.myobloc.com/hp-about/PI-5- 19-10.pdf [Accessed 2011 Mar 10].
20. Schulte-Mattler WJ. Use of botulinum toxin a in adult neurological disorders: efficacy, tolerability and safety. CNS Drugs 2008; 22 (9): 725-38.
21. Ney JP, Joseph KR. Neurologic uses of botulinum neurotoxin type A. Neuropsychiatr Dis Treat 2007 Dec; 3 (6): 785-98.
22. Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr 2005 Mar; 63 (1): 180-5. (Pubitemid 40543441)
23. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006 Apr 28; 312 (5773): 592-6.
24. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993 Sep 9; 365 (6442): 160-3. (Pubitemid 23282061)
25. Dressler D, Rothwell JC. Electromyographic quantification of the paralysing effect of botulinum toxin in the sternocleidomastoid muscle. Eur Neurol 2000; 43 (1): 13-6. (Pubitemid 30045317)
26. Finsterer J, Fuchs I, Mamoli B. Quantitative electromyography- guided botulinum toxin treatment of cervical dystonia. Clin Neuropharmacol 1997 Feb; 20 (1): 42-8. (Pubitemid 27098354)
27. Odergren T, Tollback A, Borg J. Electromyographic single motor unit potentials after repeated botulinum toxin treatments in cervical dystonia. Electroencephalogr Clin Neurophysiol 1994 Oct; 93 (5): 325-9. (Pubitemid 24314979)
28. de Paiva A, Meunier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999 Mar 16; 96 (6): 3200-5. (Pubitemid 29148868)
29. Lange O, Bigalke H, Dengler R, et al. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 2009 Jul/Aug; 32 (4): 213-8.
30. Rollnik JD, Wohlfarth K, Dengler R, et al. Neutralizing botulinum toxin type A antibodies: clinical observations in patients with cervical dystonia. Neurol Clin Neurophysiol 2001; (3A): 2-4.
31. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999 Apr; 246 (4): 265-74. (Pubitemid 29229352)
32. Mohammadi B, Buhr N, Bigalke H, et al. A long-term follow- up of botulinum toxin A in cervical dystonia. Neurol Res 2009 Jun; 31 (5): 463-6.
33. WenzelRG. Pharmacology of botulinumneurotoxin serotype A. Am J Health Syst Pharm 2004 Nov 15; 61 (22 Suppl. 6): S5-10.
34. Jitpimolmard S, Tiamkao S, Laopaiboon M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry 1998 Jun; 64 (6): 751-7. (Pubitemid 28274409)
35. Truong D, Comella C, Fernandez HH, et al. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 2008; 14 (5): 407-14.
36. Wissel J, Kanovsky P, Ruzicka E, et al. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebocontrolled, parallel group study. JNeurol 2001Dec; 248 (12): 1073-8. (Pubitemid 34134544)
37. Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010 Jun; 16 (5): 316-23.
38. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebocontrolled study. Mov Disord 2005 Jul; 20 (7): 783-91. (Pubitemid 41227144)
39. Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 1998 Jan; 64 (1): 13-7. (Pubitemid 28156531)
40. Bakheit AM, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000 Oct; 31 (10): 2402-6.
41. Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001 Nov; 8 (6): 559-65. (Pubitemid 35015221)
42. Francis HP, Wade DT, Turner-Stokes L, et al. Does reducing spasticity translate into functional benefit? An exploratory meta-analysis. J Neurol Neurosurg Psychiatry 2004 Nov; 75 (11): 1547-51. (Pubitemid 39430605)
43. Bhakta BB, Cozens JA, Chamberlain MA, et al. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000 Aug; 69 (2): 217-21. (Pubitemid 30466027)
44. Bakheit AM, Fedorova NV, Skoromets AA, et al. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 2004 Nov; 75 (11): 1558-61. (Pubitemid 39430607)
45. Pittock SJ, Moore AP, Hardiman O, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003; 15 (4): 289-300. (Pubitemid 36438734)
46. Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000 Jun; 68 (6): 707-12. (Pubitemid 30265269)
47. Eames NW, Baker R, Hill N, et al. The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response. Dev Med Child Neurol 1999 Apr; 41 (4): 226-32. (Pubitemid 29209924)
48. Baker R, Jasinski M, Maciag-Tymecka I, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, doseranging study. Dev Med Child Neurol 2002 Oct; 44 (10): 666-75. (Pubitemid 35230027)
49. Ubhi T, Bhakta BB, Ives HL, et al. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 2000 Dec; 83 (6): 481-7.
50. Ipsen. Dysport: riassunto delle caratteristiche del prodotto [online]. Available from URL: http://www.torrinomedica.it/studio/generaframe.asp? variabile=http://www.torrinomedica.it/farmaci/schedetecniche/DYSPORT.asp [Accessed 2010 Oct 26].
51. Ipsen Pharma. Dysport-300 et 500 unité s Speywood [online]. Available from URL: http://www.vidalip.net/mono graphies/fiches/VINN1077.htm [Accessed 2011 March 8].
52. Haussermann P, Marczoch S, Klinger C, et al. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 2004 Mar; 19 (3): 303-8. (Pubitemid 38961084)
53. Elston JS. The management of blepharospasm and hemifacial spasm. J Neurol 1992 Jan; 239 (1): 5-8